How to Open a Pharmaceutical Wholesale Company in Turkey: 2026 Licence, Pharmacist and Compliance Rules

First identify the regulated activity rather than the company name

A foreign investor who wants to sell medicines to pharmacies in Turkey is planning a regulated wholesale operation, not merely registering a trading company. Law No. 984 Article 1 makes the opening of a pharmaceutical wholesale establishment subject to public permission. Article 3 expressly allows a person who is not a pharmacist, or a company, to establish such an undertaking provided that a qualified pharmacist is designated as the responsible manager. The current detailed framework is the Regulation on Pharmaceutical Trading Establishments and Products Kept in Those Establishments (Ecza Ticarethaneleri ve Ecza Ticarethanelerinde Bulundurulan Ürünler Hakkında Yönetmelik), published on 15 June 2022 in Official Gazette No. 31867.

Under Regulation Articles 1, 2 and 4, the undertaking’s activity may cover sourcing, storage, sale, distribution, export and transport of defined products and active pharmaceutical ingredients. The legal classification turns on what the business actually does. A company that will own and distribute stock from its own premises must meet the provisions for an ecza ticarethanesi. A broker who negotiates but never owns or physically handles products has a different regulatory position under Article 8. A transfer centre is separately defined by Article 7. These categories should be chosen before the company signs a warehouse lease or commissions supply-chain software.

May foreign shareholders establish the business?

Law No. 984 Article 3 answers an important ownership question directly: a wholesale pharmaceutical trading establishment may be opened by non-pharmacists and by a company, on condition that a qualified pharmacist responsible manager is appointed. The rule should not be confused with the separate rules for operating a retail pharmacy under Law No. 6197. For foreign direct investment in an ordinary Turkish company, Law No. 4875 Article 3 provides the applicable equal-treatment framework, while incorporation and management are governed by the Turkish Commercial Code, including the provisions on limited companies.

Share ownership is not professional authority. A foreign investor may hold shares without personally holding a Turkish pharmacist practice licence, but the regulated establishment must still retain its qualified responsible pharmacist and the pharmaceutical trading permission. Separate analysis is required for citizenship and professional qualification conditions applying to the individual pharmacist under Law No. 6197 Articles 1–3. A foreign pharmacist diploma does not itself demonstrate authorisation to practise as a pharmacist in Turkey. A two-shareholder investment structure is therefore feasible to examine at the corporate level, but its operation depends on satisfying the pharmacy-specific rules independently.

Corporate registration does not authorise medicine distribution

The first legal stage creates an entity capable of contracting, owning assets and applying for the regulated permission. The second stage is the pharmaceutical establishment application under Regulation Articles 9–11, resulting in the activity-specific permit and responsible manager certificate only after the required evaluation and inspection. These two outcomes are separate. A trade registry announcement, a tax number, a business bank account or a broadly worded object clause is not a pharmaceutical wholesale permit. An investor should not represent an incorporated but unlicensed entity as an authorised distributor.

For a Turkish limited company, check the Turkish Commercial Code rules on formation, shareholders, managers and binding representation. The site’s guide to management and representation under TCC Articles 623 and 629 deals with signatories and third parties. The shareholder agreement should identify who approves premises, who signs the pharmacist employment agreement, who funds inspection-related improvements, and who responds to permit deficiencies. Corporate governance cannot dispense with inspection, building fitness or the responsible manager’s professional duties.

Which authority issues the pharmaceutical wholesale permission?

The Regulation identifies the competent central institution as the Turkish Medicines and Medical Devices Agency (Türkiye İlaç ve Tıbbî Cihaz Kurumu, TİTCK). Under Article 10(1), an applicant for pharmaceutical wholesale activities applies to the relevant Provincial or District Directorate of Health with the information and documents set out in Annexes 1 and 2. Article 11(1) provides for the Agency to issue the activity permit and responsible-manager certificate following the prescribed assessment and satisfactory inspection. The provincial directorate is part of the application and inspection chain; its receipt of the application is not the final licence.

The electronic processes maintained by TİTCK can be accessed through the Agency’s Electronic Application and Process Management System (EBS–ESY). Investors should verify which current forms and electronic steps apply to their legal entity and proposed address. The underlying Regulation determines required permits; an electronic portal does not permit trading earlier than the law does. The Agency also provides a licensed pharmaceutical trading establishment register, which is a useful independent check of the completed authorisation.

The permit application and evidence pack

Regulation Article 10 differentiates pharmaceutical wholesalers, transfer centres and brokers by the annexes they must supply. For an ordinary ecza ticarethanesi, Annexes 1 and 2 are the starting point. The file must identify the applicant, premises, authorised signatories, proposed operations and qualified responsible manager, together with the current annex-specific supporting evidence. A company should reconcile its trade registry information, articles of association, representatives and address before applying. A corporate document bearing a different legal name or an earlier manager may prevent the file from being treated as complete.

The Ministry of Health’s Çorum Provincial Directorate publishes a practical opening checklist covering an authorised opening application, the appointment of a pharmacist responsible manager, the establishment information form, a municipal fire safety report, and corporate registration documentation. That checklist is guidance rather than a substitute for the Regulation and its amended annexes. Notably, the 17 April 2026 amendment added an item to Annex 1 requiring the relevant pharmaceutical establishment fee receipt under Fees Law No. 492. A current filing must therefore reflect the 2026 change rather than reusing a pre-April 2026 document list.

The actual examination stages and statutory periods

Regulation Article 10(4) is decisive for incomplete files: where required information and documents are missing, the application is not taken into assessment. After a complete file is supplied, Article 10(5) requires the relevant Directorate to carry out an on-site check within fifteen days. A broker application has a different rule because it is assessed on the file without an ordinary premises inspection, although the Agency retains inspection authority in the circumstances stated by the Regulation. These distinctions prevent a wrong claim that every pharmaceutical-related commercial business follows an identical inspection route.

Article 10(7) then requires the Directorate to forward the completed documents to the Agency and sets a fifteen-day Agency review period after receipt, subject to the Regulation’s process. The same paragraph provides that the total application assessment period must not exceed ninety days. This is not a promise that every applicant receives a permit exactly fifteen or ninety days after first opening a company; document completeness and inspection findings are integral to the statutory process. Article 11(1) ties issuance to affirmative approval and satisfactory inspection. If an authority identifies deficiencies, address the specific notification and resubmit the authentic supporting evidence.

Who may be the responsible pharmacist manager?

Law No. 984 Article 3 requires a qualified pharmacist responsible manager where a non-pharmacist or company opens the wholesale establishment. Regulation Article 14(1) requires each ecza ticarethanesi to operate with a pharmacist as mesul müdür and states that TİTCK issues that professional manager’s certificate. Law No. 6197 Article 1 further states that pharmaceutical warehouse responsible management requires pharmacist status. A sales director or overseas shareholder cannot perform this regulated function merely because the business agreement calls that person the director.

Regulation Article 14(2) puts responsibility for compliant sourcing, safeguarding, selling, distributing and exporting defined products and active substances on the pharmacist, within the good distribution practice framework. Article 14(4) requires the responsible manager to be physically on duty during the establishment’s service hours. Article 14(5) restricts other work except qualifying elected positions as described there. These are professional requirements, not optional preferences in a private employment contract. The investor must budget for a genuinely qualified manager and build governance that permits the manager to discharge independent regulatory responsibilities.

What if the responsible manager resigns or is absent?

A pharmaceutical wholesaler should not improvise its compliance response after the pharmacist resigns. Regulation Article 14(9) requires the establishment owner to notify the Directorate within five working days when the responsible manager position becomes vacant and to return the previous certificate for cancellation. An application to appoint a replacement must be made through the Directorate to TİTCK within fifteen working days from the vacancy, with the required documents. The Regulation provides for suspension of the establishment’s permission and activity if that replacement requirement is not fulfilled.

Article 14(6) sets rules for short absences and temporary substitutions. Absence for up to one week requires written notification; longer periods extending from one week up to two months require the substitute pharmacist arrangement described in the Regulation. Article 14(7) addresses absences over two months and the need for a new appointment, otherwise suspension applies. Article 14(3) requires a separate responsible manager for each branch. Employment contracts, annual leave records, emergency replacement plans and electronic notifications should be structured around these express legal requirements rather than an informal promise that a visiting pharmacist can sign documents when needed.

Premises, storage layout and physical suitability

Regulation Article 6(1) demands premises with sufficient and appropriate buildings, installations, equipment, capacity, physical organisation and qualified personnel to preserve and distribute products under the required storage conditions. This is why choosing an office address for trade-registry purposes does not establish warehouse suitability. Article 6(2) requires separate storage of product categories where the Regulation so provides. Article 6(3) entrusts further detailed requirements on physical areas, staffing, quality systems, dispatch, complaints and contracted operations to applicable guidance.

Before renting a property for regulated storage, obtain the building’s permitted use and fire compliance records, inspect its suitability for controlled access, quarantine storage, receipt/dispatch segregation, refrigeration and continuous environmental monitoring. Commercial lease wording should allocate responsibility for alterations required by the authorised layout without allowing unauthorised operations before the permit. A proper evidence file includes the signed lease or ownership evidence, site plans, fire report, equipment records, calibration records, monitoring validation and the precise premises address that will appear on the eventual permit.

Cold-chain products and continuous temperature monitoring

Regulation Article 17(1) requires products and active substances to be stored under the conditions applicable to them, with appropriate facilities and records for products requiring special storage. Article 17(2) expressly requires an effective alarm system when temperatures or humidity levels in storage areas move outside defined limits. Article 17(3) requires appropriate temperature and humidity during carriage, as well as precautions against damage and theft. A fridge alone is therefore not the complete legal answer: the establishment must maintain a demonstrable chain of controlled conditions.

The system of records should connect product batch, receipt temperature, storage zone, monitored excursions, any quarantine decision, dispatch date and the recipient. For products moved between a warehouse and transport operator, contractual records should show where the transfer of physical custody occurred and who reviewed alarm events. A data logger whose data is never downloaded or reviewed is not sufficient operational evidence. A deviation procedure should identify affected batches, prevent dispatch of questionable stock, record professional assessment and permit effective withdrawal when required.

Who may buy from a licensed pharmaceutical trading establishment?

Regulation Article 9(6) sets out the ordinary authorised destinations for the defined products and active ingredients: pharmacies, human medicinal-product manufacturing establishments and other pharmaceutical trading establishments, followed by specified exceptional destinations subject to the conditions in the paragraph. These rules must be read in full against each product category. Article 9(7) prohibits wholesale or retail sale to individuals outside the exception specified by Law No. 984 Article 11. A direct-to-patient e-commerce business is not made lawful simply by opening an ecza ticarethanesi.

For special destinations, Article 9(6) includes conditional rules for listed products supplied to places authorised under the relevant legislation, research supplies approved by TİTCK, certain veterinary product sales to authorised veterinary establishments, and particular vaccine supplies for immunisation without a commercial purpose. The same paragraph restricts sales of narcotic, psychotropic or precursor products between separate trading establishments, subject to the stated branch exception. Sales permissions should be mapped product by product. The company must not infer authority to supply hospitals, wholesalers, consumers or foreign businesses merely from an unrestricted business-purpose clause in its articles.

Product categories and the danger of mixing licences

The Regulation’s defined “product” category in Article 4 includes human medicinal products, foods for special medical purposes and pharmacy-compounding materials, subject to its explicit exclusions. Article 9(5) also describes other categories that an establishment may handle where the relevant sector-specific law and the Regulation permit the activity. A wholesaler that plans to trade medicines, medical devices, cosmetics, food supplements and veterinary products must therefore build a product matrix identifying the governing authorisation and supply rules for each class.

One category’s permission does not automatically cover another’s restrictions. The fact that a company sells medical devices under an applicable device regime does not establish authorisation for human medicine distribution. Equally, a medicine wholesale establishment cannot treat an active pharmaceutical ingredient in the same way as an ordinary consumer cosmetic ingredient without checking the regulatory definition and relevant product controls. During formation, contractual objects may be broad, but operational marketing should be narrow and faithful to the approvals actually granted.

Wholesale distribution is not pharmaceutical manufacturing

Regulation Article 9(10) expressly prohibits manufacturing activities such as dividing, splitting or repackaging within pharmaceutical trading establishments. The definitions in Article 4 distinguish activities such as handling without changing fundamental product qualities from pharmaceutical manufacturing operations. An investor should not build a commercial plan based on receiving bulk medicine, relabelling units or dividing packs for local sale under a mere wholesale establishment permission.

For manufacturing, different establishment permissions and good manufacturing practice requirements arise under the separate manufacturing legislation. The wholesale authorisation allows only the activities and location stated in the issued permit under Article 9(3). A manager should examine every proposed handling step: receiving sealed product, retaining it in approved conditions, dispatching to an authorised purchaser and documenting its traceability are not equivalent to modifying pharmaceutical packaging. If an outsourced contractor changes the product’s pack or labelling, responsibility and the required permits must be assessed before contracting.

İTS: traceability and penalties under the 2025 amendment

Regulation Article 18(5) requires movements of products covered by the Drug Tracking System (İlaç Takip Sistemi, İTS) to be reported, and it requires consistency between electronic notifications and physical stock, recipient and quantity records. Article 18(6) separately addresses reporting of pharmaceutical exports through the system. This obligation was reinforced by Additional Article 1 of Law No. 984, inserted by Law No. 7557 on 21 July 2025, which addresses reporting movements of human medicines and foods for special medical purposes throughout the supply chain.

The statutory consequence is specific and substantial: for the first identified reporting contravention, the fine is calculated as twice the total wholesale selling price of the products involved on the detection date; a repeat of the same contravention within one year increases the administrative fine by one further multiple; the third detection leads to cancellation of the establishment licence. This is not a general fine that can accurately be expressed as a fixed Turkish-lira number for every case. Implement reconciliation between transactions, serialisation data, invoices and physical stock from the start, and preserve the records needed to explain any discrepancy to TİTCK.

What records does a pharmaceutical wholesaler have to retain?

Regulation Article 18(1) requires order, purchase, sale, distribution, return, disposal and stock records appropriate to the activity, with product name, batch, expiry, quantities, counterparties and traceability data. Article 18(3) requires electronic storage of temperature and humidity monitoring records; Article 18(4) requires personnel records. Under Article 18(9), all records concerning the activities within the Regulation must be retained at the place of operation for five years. The retention obligation is not replaced by forwarding spreadsheets to an accountant once per month.

The operator should create a coherent document architecture, linking each supplier, recipient and product movement to the underlying records. Make access rights specific to the responsible manager, quality staff, authorised signatories and professional advisers. Backups should preserve completeness and integrity. When data involves individuals, Personal Data Protection Law No. 6698 must be considered separately; a traceability duty does not mean that every employee may access all customer data. An evidentiary archive enables recall, inspection and contractual reconciliation and also reduces risk when different shareholders control finance and operations.

Recall planning and defective or suspicious stock

Regulation Article 5(3) prohibits sale of unlicensed, counterfeit, expired, incorrectly manufactured, altered, damaged and withdrawn products. Under Article 5(4), products identified or suspected to fall within specified categories must be reported without delay to the competent authority, affected institutions and the marketing authorisation holder as applicable. The Regulation also requires isolation of affected batches in a physically separated locked area and electronic sale controls pending the competent decision. Such stock is not ordinary inventory available for a discount sale.

Article 6(4) requires a distribution record system that enables prompt withdrawal, an emergency action plan and a procedure complying with the applicable Recall Regulation. The establishment should be able to find all destinations for a particular batch and separate returned, recalled or disposal stock from current saleable products. A contract giving another company responsibility for transport or IT does not remove these public-law duties. Testing traceability before the first commercial dispatch is a practical way to detect missing serial numbers, recipient identifiers and reversal records.

Logistics outsourcing, transfer centres and brokers

A foreign shareholder may prefer to outsource transport, refrigerated storage or order management. Regulation Article 19(1) permits regulated service relationships on the basis of a contract clearly identifying duties and responsibilities and providing for supervision of good distribution practice. The same provision explicitly states that a contract does not remove the parties’ responsibilities toward TİTCK. A logistics provider’s insurance or ISO certificate cannot alone replace the regulatory permission required for the particular activity.

Regulation Article 7 describes transfer centres and their temporary storage conditions, including a maximum holding period of seventy-two hours. Regulation Article 8 describes a broker who may mediate the sale or purchase of authorised products but may not distribute them, physically handle them, take ownership or sell them in its own name or on another’s behalf. Article 10 specifies separate annexes and application treatment for these distinct models. The business plan must identify the actual custody, ownership and sale functions; relabelling a warehouse operator as a “broker” does not change the operation’s legal nature.

Exporting medicines from Turkey: a separate controlled workflow

Regulation Article 9(9) permits export activity by pharmaceutical trading establishments subject to the relevant legislation, required Drug Tracking System notifications and the destination country’s applicable law. The export permission in a wholesale permit does not authorise sale of every product to every foreign market. The permitted product, lawful supplier, Turkish distribution record, shipment documentation, destination requirements and any specific product controls need to be identified before a contract guarantees delivery.

Article 18(6)–(8) requires reconciliation of export notifications with destination country and company documents, appropriate notification to the receiving country’s health authority and TİTCK if problems arise, and retention of relevant customs declarations and serial-number details for presentation. Separately, the Regulation’s Additional Article 1 addresses narrowly defined export activities outside the ordinary wholesale establishment structure for qualifying manufacturers and authorisation holders. Investors must not treat that exception as a general workaround. The site’s guide to customs clearance for foreign importers

The April 2026 changes investors must put into the application

The amendment published on 17 April 2026 in Official Gazette No. 33227 made two targeted changes to the 2022 Regulation. First, Article 21(1)(b) now states that deficiencies identified during inspections are documented with the signature of the responsible manager or responsible employee and that the inspection can also be recorded through the Agency’s electronic systems and software. Second, Annex 1 received a new item requiring the pharmaceutical establishment fee receipt payable under Fees Law No. 492. The changes were effective upon publication.

Consequently, an investor working from an older checklist cannot assume that a permit file is complete without checking the applicable fee receipt. The text does not establish one universally payable amount in this guide; the assessed fee and official payment record must be verified against the actual application and current charges. Inspection minutes also matter in electronic form. A manager should preserve both the signed or authenticated inspection documentation and evidence of the actual remedial actions taken after any finding. The most reliable compliance checklist is the current consolidated Regulation alongside the applicable Ministry and TİTCK procedural instructions.

Corporate taxation, residence and work rights are not created by the licence

Pharmaceutical licensing and ordinary tax registration perform different tasks. The wholesale permit confirms the right to carry out specified regulated pharmaceutical activities at an approved address under the responsibility of the designated pharmacist. Corporate income tax, VAT, payroll, withholding and accounting records follow their respective tax statutes and the company’s actual transactions. The site’s 2026 corporate-tax guide for foreign-owned Turkish companies

Owning shares also does not automatically give a foreign investor a Turkish residence or work permit. A foreign national who will undertake employment or management activity in Turkey must assess the applicable immigration and work-permission rules, including International Labour Force Law No. 6735 and Foreigners and International Protection Law No. 6458. The site’s work-permit and residence-permit guide

A legally sequenced roadmap for two or more foreign investors

The correct starting point is a concise activity definition: which human medicines or ingredients will be traded, whether the company will hold stock or only act as a broker, who will buy, which Turkish premises will store products and which countries will receive exports. The shareholders then determine the corporate form, appoint a legally authorised company representative and register the business. In parallel, they identify a pharmacist satisfying the professional requirements, examine the suitability of premises and gather the authentic annex documents, including current fees and fire evidence.

The next stage is the formal application to the Provincial Directorate under Regulation Article 10, followed by the prescribed inspection and TİTCK review. Operational readiness is documented through training, calibrated monitoring, traceability, quarantine, returns, recall, approved purchaser checks and lawful transport arrangements. Commercial supply contracts should not require unlawful pre-permit dispatch. After issuance, the company must operate only within the activities and address recorded in the permit, monitor manager vacancies and maintain the five-year activity records. Bakırcı & Keskin Law Office can assist with legal-document preparation, registration coordination and licensing-related administrative submissions; company and accounting work can be coordinated with an independent qualified accountant.

Frequently asked questions

Primary legal sources

• Official Gazette No. 31867, 15 June 2022: Regulation on Pharmaceutical Trading Establishments
• Ministry of Health, Antalya Provincial Directorate: 17 April 2026 amendment, Gazette No. 33227
• Ministry of Health, Çorum Provincial Directorate: pharmaceutical warehouse application documents
• Ministry of Health, Law No. 6197, Pharmacists and Pharmacies (check against amendments)
• TİTCK Electronic Application and Process Management
• TİTCK Licensed Pharmaceutical Trading Establishments Register

Additional legislation: Law No. 984 Articles 1–4 and Additional Article 1 as amended by Law No. 7557 (24 July 2025); Law No. 6197 Articles 1–3; Turkish Commercial Code; and Fees Law No. 492. Read the 2022 Regulation as consolidated with subsequent changes. An older official checklist does not replace a newer amendment.